Please login to the form below

Not currently logged in
Email:
Password:

Egalet appoints Stan Musial as CFO

Joins US pharma company after a two-year spell as a start-up consultant

Stan Musial has joined US pharma company Egalet as chief financial officer having spent the past two years as an independent consultant for start-up businesses.

His most recent in-house role was as chief financial officer at Prism Pharmaceuticals, where he served from 2005 to 2011 before its sale to Baxter Healthcare.

Prior to joining Prism, Musial held the position of VP, finance, and chief financial officer for Strategic Diagnostics.

Egalet is a company that specialises in developing abuse-deterrent medication via a platform that prevents easy extraction and deters abuse of drugs through known routes, such as chewing, snorting, and injecting.

The company's president and chief executive Bob Radie said: "The addition of Stan to the management team comes at a critical time as the most advanced products in Egalet's pipeline of abuse-deterrent opioids are nearing phase III.

"Stan's finance experience will be invaluable as we move our pipeline through development and ultimately to the commercial market."

10th May 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics